Dianthus Therapeutics to Participate in Two Upcoming Investor Conferences
Provided By GlobeNewswire
Last update: Feb 26, 2025
NEW YORK and WALTHAM, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the company’s participation at the following investor conferences:
Read more at globenewswire.com
